Belite Bio, Inc - Price Target for Depositary Receipt (BLTE) Raised by 62.05% to 188.02
Written by Emily J. Thompson, Senior Investment Analyst
Source: NASDAQ.COM
Updated: 1 hour ago0mins
Revised Price Target: The average one-year price target for Belite Bio, Inc. has been increased to $188.02 per share, reflecting a 62.05% rise from the previous estimate of $116.02.
Analyst Range: Current analyst targets for Belite Bio range from a low of $141.40 to a high of $210.00 per share, indicating a 24.29% increase from the last reported closing price of $151.27.
Fund Sentiment: There has been a significant increase in institutional interest, with 45 funds reporting positions in Belite Bio, a 50% rise in the last quarter, and total shares owned by institutions increasing by 2,316.22% to 2,304K shares.
Major Shareholders: Key institutional shareholders include Ra Capital Management with 875K shares, Rtw Investments and Vestal Point Capital each with 312K shares, and Soleus Capital Management with 210K shares.
BLTE.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on BLTE
Wall Street analysts forecast BLTE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLTE is 113.75 USD with a low forecast of 85.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 151.270
Low
85.00
Averages
113.75
High
140.00
Current: 151.270
Low
85.00
Averages
113.75
High
140.00
Maxim
NULL -> Buy
maintain
$140 -> $200
2025-12-02
New
Reason
Maxim
Price Target
$140 -> $200
2025-12-02
New
maintain
NULL -> Buy
Reason
Maxim raised the firm's price target on Belite Bio to $200 from $140 and keeps a Buy rating on the shares after the company reported positive topline results from the Phase 3 DRAGON trial of tinlarebant in adolescent Stargardt disease.
Mizuho
Graig Suvannavejh
Neutral -> Outperform
upgrade
$194
2025-12-02
New
Reason
Mizuho
Graig Suvannavejh
Price Target
$194
2025-12-02
New
upgrade
Neutral -> Outperform
Reason
Mizuho analyst Graig Suvannavejh upgraded Belite Bio to Outperform from Neutral with a $194 price target.
Mizuho
Graig Suvannavejh
Neutral -> Outperform
upgrade
$105 -> $194
2025-12-02
New
Reason
Mizuho
Graig Suvannavejh
Price Target
$105 -> $194
2025-12-02
New
upgrade
Neutral -> Outperform
Reason
Mizuho analyst Graig Suvannavejh upgraded Belite Bio to Outperform from Neutral with a price target of $194, up from $105. The firm cites the positive Phase 3 data for tinlarebant in Stargardt disease for the upgrade. The data are "impressive" and better than Mizuho's expectations on both efficacy and safety, the analyst tells investors in a research note. The firm increased its probability of success assumptions for tinlarebant to 85% from 40%-60% prior. Mizuho sees the drug's U.S. launch pricing at $350,000 and moved up its risk-unadjusted tinlarebant sales estimate to $4.2B. It sees further upside in the shares post the data.
Cantor Fitzgerald
NULL -> Overweight
initiated
$154
2025-11-24
Reason
Cantor Fitzgerald
Price Target
$154
2025-11-24
initiated
NULL -> Overweight
Reason
Cantor Fitzgerald assumed coverage of Belite Bio with an Overweight rating and $154 price target. Belite is set to report Phase 3 data this quarter for tinlarebant in Stargardt disease, with the readout notable because the one-year futility analysis already achieved statistical significance, the FDA granted breakthrough designation based on that interim success, and multiple regulators, including in China and the U.K., have agreed to accept filings using the interim data, the analyst tells investors in a research note.
See All Ratings
About BLTE
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What factors led HC Wainwright & Co. to reaffirm a buy rating?
How does Tinlarebant reduce retinal lesion growth in Stargardt disease patients?
Will Belite Bio's stock price increase after the Phase 3 trial success?
How might the $350 million public offering impact Belite Bio's market position?